BRIEF-Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial

Reuters10-08

Oct 8 (Reuters) - Regulus Therapeutics Inc :

* REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

* REGULUS THERAPEUTICS INC: REMAIN ON TRACK FOR AN END OF PHASE 1 MEETING WITH FDA BY END OF 2024

* REGULUS THERAPEUTICS INC - PLANS TO SHARE TOPLINE DATA IN EARLY 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473426091?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473426091","market":"us","top_or_hot":-1,"title":"BRIEF-Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial","media":"Reuters","content":"<html><body><p>Oct 8 (Reuters) - <a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a>   :</p><p>   * REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> OF PHASE 1B MULTIPLE-ASCENDING DOSE <a href=\"https://laohu8.com/S/MAD.AU\">$(MAD.AU)$</a> CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)</p><p>   * REGULUS THERAPEUTICS INC: REMAIN ON TRACK FOR AN END OF PHASE 1 MEETING WITH FDA BY END OF 2024</p><p>   * REGULUS THERAPEUTICS INC - PLANS TO SHARE TOPLINE DATA IN EARLY 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 20:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 8 (Reuters) - Regulus Therapeutics Inc   :   * REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL OF RGLS8429 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGLS","symbol_name":"Regulus Therapeutics Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2473426091","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473426091","pubTimestamp":1728389259,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 8  - Regulus Therapeutics Inc   :   * REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE  CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE    * REGULUS THERAPEUTICS INC: REMAIN ON TRACK FOR AN END OF PHASE 1 MEETING WITH FDA BY END OF 2024   * REGULUS THERAPEUTICS INC - PLANS TO SHARE TOPLINE DATA IN EARLY 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGLS":"Regulus Therapeutics Inc","BK4139":"生物科技"},"translate_title":"简介-Regulus Therapeutics宣布完成1B期多次递增剂量临床试验第四队列的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGLS":1},"content_text":"Oct 8 (Reuters) - Regulus Therapeutics Inc   :   * REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE $(MAD.AU)$ CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)   * REGULUS THERAPEUTICS INC: REMAIN ON TRACK FOR AN END OF PHASE 1 MEETING WITH FDA BY END OF 2024   * REGULUS THERAPEUTICS INC - PLANS TO SHARE TOPLINE DATA IN EARLY 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473426091"}